The COVID-19 Patient Confidence Study, a weekly measure of consumer attitudes and behavior, shows that consumer confidence is at the highest levels since the onset of COVID-19.
72% of patients have reported that they are not delaying a doctor visit to discuss a condition. In addition, the majority of patients expect to go to the HCP in the next two months or sooner, while only 37% expected to go in the next two months on April 30.
86% of consumers are comfortable visiting healthcare providers, over twice the confidence of visiting a restaurant or the 36% comfortable attending a public gathering such as a rock concert or sports event.
Physician search has significantly increased across the country from late March. For example, in Nevada, there was an increase of 129%; in Texas, there was an increase of 111%; and in New York an increase of 114%.
The research also shows that telemedicine has played an important role in delivering care. According to the survey, 30% of respondents have participated in telemedicine in the past 3 months and 83% are open to interacting with their care provider virtually.
Infosurv Research is a boutique research agency based in Atlanta, GA.
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering